Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Emtricitabine/tenofovir alafenamide for PrEP in the UK

Monday 16 May 2022

Emtricitabine/tenofovir alafenamide as Descovy® was recently granted a licence extension by the MHRA so that it can be used as PrEP in the four UK countries without this use being ‘off label’. Descovy® for PrEP is already approved by the American FDA.

As tradenames for preparations containing this combination vary according to indication, we have now two entries for emtricitabine/tenofovir alafenamide on the website:

  • Emtricitabine/tenofovir alafenamide (trade names: Descovy, Taficita, Kocitaf (with dolutegravir))
  • Emtricitabine/tenofovir alafenamide for PrEP (trade names: Descovy, PrEP)
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016